Bradley Foster & Sargent Inc. CT Sells 30,390 Shares of Zoetis Inc. $ZTS

Bradley Foster & Sargent Inc. CT decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 14.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 175,277 shares of the company’s stock after selling 30,390 shares during the quarter. Bradley Foster & Sargent Inc. CT’s holdings in Zoetis were worth $25,647,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Halbert Hargrove Global Advisors LLC increased its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the period. NewSquare Capital LLC lifted its stake in shares of Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after acquiring an additional 85 shares during the period. Financial Consulate Inc. bought a new stake in Zoetis in the third quarter valued at approximately $39,000. SJS Investment Consulting Inc. increased its position in Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after purchasing an additional 257 shares during the period. Finally, TruNorth Capital Management LLC bought a new position in Zoetis during the 3rd quarter worth approximately $42,000. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of ZTS opened at $128.70 on Wednesday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.00. The company has a market cap of $54.33 billion, a PE ratio of 21.38, a P/E/G ratio of 1.92 and a beta of 0.96. The stock has a 50-day moving average of $125.61 and a 200-day moving average of $134.35. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.6%. Zoetis’s dividend payout ratio is presently 35.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Morgan Stanley set a $160.00 price objective on shares of Zoetis in a research note on Thursday, December 18th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday. UBS Group set a $136.00 price objective on Zoetis in a research report on Thursday, January 29th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $135.00 target price (down from $190.00) on shares of Zoetis in a research note on Thursday, January 22nd. Five investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Zoetis has a consensus rating of “Hold” and a consensus price target of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.